Intercept Pharmaceuticals, Inc. (ICPT)의 가격은 얼마입니까?

Intercept Pharmaceuticals, Inc. (ICPT)의 가격은 $19.00입니다.

Intercept Pharmaceuticals, Inc. (ICPT)의 시가 총액은 무엇입니까?

Intercept Pharmaceuticals, Inc. (ICPT)의 시가 총액은 $629.64M입니다.

Intercept Pharmaceuticals, Inc. (ICPT) PSR

Intercept Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the advancement and market launch of therapies designed to treat progressive, non-viral liver conditions. Its operational reach spans the United States, Europe, and Canada. The company currently markets Ocaliva, a medication functioning as a farnesoid X receptor (FXR) agonist. This drug is approved for the treatment of primary biliary cholangitis (PBC) in adults, specifically when administered alongside ursodeoxycholic acid. Beyond its existing approved indications, Intercept is actively investigating Ocaliva's potential for additional uses, notably including nonalcoholic steatohepatitis (NASH). Concurrently, it is progressing other drug candidates through various clinical and preclinical stages of development. In a collaborative effort, the company holds a licensing agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. Intercept distributes its products through a dual approach, utilizing both its proprietary commercial organization and a network of external third-party distributors. The company was founded in 2002 and is headquartered in New York, New York.

연도	P/S 비율	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

P/S 비율

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	P/S 비율	P/S 비율 차이	국가
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	-	US
Argenx SE ARGX.US	10.13	-	NL
CSL Limited CSL.AX	2.95	-	AU
Moderna, Inc. MRNA.US	11.28	-	US
Lonza Group AG LONN.SW	-	-	CH

회사

P/S 비율

P/S 비율 차이

국가